UroGen Pharma (URGN) reported Q3 EPS of ($1.13), $0.03 better than the analyst estimate of ($1.16). Revenue for the quarter came in at $16.01 million versus the consensus estimate of $20.15 million.
UroGen Pharma (URGN) reported Q3 EPS of ($1.13), $0.03 better than the analyst estimate of ($1.16). Revenue for the quarter came in at $16.01 million versus the consensus estimate of $20.15 million.